>> OKAY.
SO ALL OF YOU ARE AWARE THAT THE JAPANESE ENCEPHALITIS VACCINE
WORK GROUP COMPLETED SOME OF ITS WORK AND CONTINUING TO DO
ADDITIONAL WORK-RELATED TO JE VACCINE AND THAT IS REVISION OF
THE CURRENT STATEMENT. BUT IN ADDITION THERE WAS A
RECENT CHANGE IN THE RECOMMENDATION OF THE BOOSTER
DOSE OF THE YELLOW FEVER AND WE WERE ASKED TO ADD THIS TO OUR
AGENDA TO REVIEW AND COME FORWARD WITH RECOMMENDATIONS TO
THE ACIP. SO AS YOU KNOW, IN THE UNITED
STATES, THERE IS A SINGLE VACCINE LICENSE TO PROVIDE
PROTECTION AGAINST YELLOW FEVER. IT'S A LIVE ATTENUATED VACCINE.
THE ONLY VACCINE LICENSE AS I SAID.
IT'S RECOMMENDED FOR THOSE
PEOPLE RESIDING IN OR TRAVELING TO YELLOW FEVER ENDEMIC AREAS.
AND IN ACCORDING WITH THE INTERNATIONAL HEALTH
REGULATIONS, ACIP CURRENTLY RECOMMEND BOOSTER DOSE EVERY TEN
YEARS. THEY WERE UPDATED IN 2009 AND
PUBLISHED IN 2010. IN APRIL OF THIS YEAR, IT WAS
CONCLUDED A SINGLE DOSE IS SUFFICIENT TO CONFER SUSTAINED
IMMUNITY AND LIFE LONG PROTECTION AGAINST YELLOW FEVER
DISEASE. AND THEREFORE RECOMMENDED THAT
NO LONGER RECOMMENDED BOOSTER DOSES, INDICATING THAT THEY WERE
NO LONGER NEEDED.COUNTRIES CAN STILL REQUIRE YELLOW
FEVER VACCINE BOOSTER DOSES UNDER INTERNATIONAL HEALTH
REGULATIONS.
SO WE WERE GIVEN THE TASK TO REVIEW AND MAKE RECOMMENDATIONS.
WE'RE CURRENTLY RESTRUCTURING THE JE VACCINE WORK GROUP TO
FORM THE JE AND YELLOW FEVER VACCINE WORK GROUP.
OUR GOAL IS TO REVIEW FAILURE DATA AND RECOMMENDATIONS
REGARDING BOOSTER DOSES FOR U.S. TRAVELERS AND LABORATORY WORKERS
WHO HAVE CONTACT WITH THE VIRUS. WE ANTICIPATE TO HAVE THIS WORK
DONE AND BRING THE INFORMATION FORWARD TO ACIP FOR A VOTE ON
THE BOOSTER DOSE IN 2014. AND HERE ARE THE CURRENT MEMBERS
OF THE JE AND YELLOW FEVER VACCINE WORK GROUP.
AND I THINK THIS IS A GROUP THAT THAT HAS EXPERIENCE AND CAN
BRING FORWARD APPROPRIATE RECOMMENDATIONS TO THE ACIP.
THANK YOU. >> ANY QUESTIONS FOR DR.
BOCCHINI? >> I WOULD ASSUME THAT WE WOULD
USE THE REVIEW AND JUST HAVE TO UPDATE IT?
>> YEAH, I THINK THAT'S EXACTLY RIGHT.
WE WILL CERTAINLY LOOK AT THE REVIEW AND THEN SEE IF THERE IS
A TISHL ADDITIONAL PUBLISHED OR P PUBLISHED DATA.
AND WE ALSO NEED TO DETERMINE IF THERE ARE DIFFERENT REQUIREMENTS
FOR ACIP IN TERMS OF THAT REVIEW.
>> OTHER DISCUSSION OR COMMENT? AS YOU'RE MAKING YOUR PLANE
FLIGHT TOMORROW ON TIME, PUT A NICE THOUGHT FOR DR. BOCCHENI'S
WILLINGNESS TO COME UP HERE AND DO THIS WITHOUT ANY PROMPTING.
TWO OTHER POINTS.
NUMBER ONE, HE HAD MENTIONED THE SAGE RECOMMENDATION COMING FROM
WORLD HEALTH AND DR. ABRAHAMSON WILL BE HERE TOMORROW GIVING
UPDATES ON GLOBAL PERSPECTIVES. AND THE OTHER THING IS I'LL
MENTION EBL WE'I BELIEVE WE'RE FINISHING EARLY ENOUGH THAT WE
CAN COME BACK AT 1:15 TO START THE AFTERNOON SESSION A LITTLE
BIT EARLY. SO WITH THAT, WE WILL BREAK FOR
LUNCHTIME. THANK YOU.